pre-IPO PHARMA

COMPANY OVERVIEW

INOTREM SA is a biopharmaceutical company discovering and developing first-in-class immunotherapies for the treatment of inflammatory diseases. The Company is developing a new concept of immunomodulation targeting the amplification loops of the innate immune response with an initial focus on septic shock.


LOCATION

  • Paris, , France

  • THERAPEUTIC AREAS

  • Cardiovascular Disease
  • Infectious Disease

  • WEBSITE

    https://www.inotrem.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    andera-partners biomed-ventures edmond-de-rothschild-investment-partners inserm-transfert-initiative sofinnova-partners sofinnova-ventures


    PRESS RELEASES


    Jun 1, 2023

    Inotrem Announces Publication of Two Key Articles on Nangibotide Phase II Programs in Peer-reviewed Medical Journals


    Jan 9, 2023

    Inotrem Receives Funding From the Crohn’s and Colitis Foundation to Help Develop New Therapeutic Approaches in Inflammatory Bowel Disease (IBD)


    Oct 25, 2022

    Inotrem Announces That Its ESSENTIAL Phase II Study for the Treatment of Critically ill COVID-19 Patients Meets Its Primary and Key Secondary Endpoints


    Oct 13, 2022

    Inotrem Announces Positive Outcome of its Phase II ASTONISH Trial in Septic Shock Patients Demonstrating Efficacy of Nangibotide


    Apr 14, 2022

    Inotrem and the Crohn’s and Colitis Foundation Sign a RandD Collaboration Agreement to Support the Development of a New Therapeutic Approach in Inflammatory Bowel Disease (IBD)


    For More Press Releases


    Google Analytics Alternative